Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies
Background: The use of direct oral anticoagulants (DOACs) is recommended as the preferred treatment drug in patients with nonvalvular atrial fibrillation (AF). However, the effectiveness and safety of DOACs compared with vitamin K antagonists (VKAs) in patients with cancer and AF are still controver...
Guardado en:
Autores principales: | Fuwei Liu, Zixuan Xu, Jun Luo, Peng Yu, Jianyong Ma, Ping Yuan, Wengen Zhu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b324455df1fc4310aac2e7289142aeda |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention
por: Marek Koziński, et al.
Publicado: (2020) -
Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Gilda Denise Zielinski, et al.
Publicado: (2020) -
Low Dose of Direct Oral Anticoagulants after Left Atrial Appendage Occlusion
por: Pedro Luis Cepas-Guillen, et al.
Publicado: (2021) -
New Oral Anticoagulants vs. Vitamin K Antagonists Among Patients With Cardiac Amyloidosis: Prognostic Impact
por: Eve Cariou, et al.
Publicado: (2021) -
Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile
por: Corbalán,Ramón, et al.
Publicado: (2017)